SCHEMBL2984545

SCHEMBL2984545

Fc1ccc(C2=C[N+]3(Cl)N=CN=C3C=N2)c(F)c1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9135463 0.59 ALDH1A1 (0.52)
SCHEMBL10880616 0.58 KMO (0.35)
SCHEMBL15928205 0.57 KMO (0.34)
SCHEMBL20654512 0.55 AKR1C3 (0.50)
SCHEMBL29534134 0.55 AKR1C3 (0.50)
SCHEMBL13674310 0.54 NFE2L2 (0.50)
SCHEMBL6130746 0.53 CCR1 (0.50)
SCHEMBL503953 0.53 CCR1 (0.55)
SCHEMBL30224316 0.53 KMO (0.42)
SCHEMBL1537654 0.53 ALPL (0.40)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2229392-A1 TRIAZOLOTRIAZINES AND TRIAZOLOPYRAZINES AND THEIR USE AS GSK3BETA INHIBITORS Bayer Schering Pharma Aktiengesellschaft (DE) 2010-09-22 EP disclosed
US-20090258877-A1 TRIAZOLOTRIAZINES AND TRIAZOLOPYRAZINES AND THEIR USE BAYER HEALTHCARE AG (DE) 2009-10-15 US disclosed
WO-2009074259-A1 TRIAZOLOTRIAZINES AND TRIAZOLOPYRAZINES AND THE USE THEREOF BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2009-06-18 WO disclosed